What is Lymphangioleiomyomatosis (LAM)?
Lymphangioleiomyomatosis (LAM) is a rare, systemic neoplastic disease that almost exclusively affects women of reproductive age, characterized by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to cystic lung destruction, lymphatic involvement with chylous fluid accumulations, and abdominal tumors including angiomyolipomas and lymphangioleiomyomas 1.
Pathophysiology
LAM is caused by mutations in the TSC1 or TSC2 genes, which encode hamartin and tuberin respectively—two proteins that control the mechanistic target of rapamycin (mTOR) signaling pathway 2. These LAM cells coexpress smooth muscle and melanocytic markers and have metastatic potential 3, 4. Female hormones, particularly estrogens, significantly influence disease progression 4.
Clinical Presentation
LAM occurs in two forms:
- Sporadic LAM: Occurs independently in women
- TSC-associated LAM: Occurs in patients with tuberous sclerosis complex, an autosomal-dominant syndrome 5
Common Symptoms
- Progressive dyspnea (most frequent symptom at diagnosis) 6
- Recurrent spontaneous pneumothorax (typical presentation) 6, 2
- Chest pain and coughing 4
- Chylothorax (chylous pleural effusions) 1
Extrapulmonary Manifestations
Diagnostic Features
Pulmonary function testing reveals reduced flow rates (FEV₁) and decreased lung diffusion capacity 2, 5. Exercise testing may demonstrate hypoxemia and ventilatory limitation 2.
Imaging shows characteristic diffuse pulmonary cysts on computed tomography 1.
A critical diagnostic algorithm: For patients with characteristic cystic abnormalities on CT but lacking confirmatory features (tuberous sclerosis complex, angiomyolipomas, chylous effusions, or lymphangioleiomyomas), VEGF-D testing should be performed before considering lung biopsy 1.
Prognosis and Natural History
LAM is a slowly progressive disease with variable clinical phenotypes and rates of progression 2. Recent advances in understanding the molecular mechanisms and the introduction of mTOR inhibitors have significantly improved prognosis 3. The disease severity can be assessed through CT quantification, pulmonary function testing, 6-minute walk tests, and serum VEGF-D levels 5.